<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558882</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2011/VL-05</org_study_id>
    <secondary_id>2012-A00253-40</secondary_id>
    <nct_id>NCT01558882</nct_id>
  </id_info>
  <brief_title>Impact of Essure Tubal Sterilization Devices on the Endometrium</brief_title>
  <official_title>Impact of Essure Tubal Sterilization Devices on the Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mobilization of natural killer cells (uNK) triggers and coordinates all stages of embryo
      implantation. They are at the origin of the local secretion of cytokines, growth factors,
      chemokines affecting vascular development and the local immunotrophisme for the conceptus.
      The main objective of this study is to evaluate the expression of endometrial uNK cells
      before and after tubal obstruction by Essure devices. Endoluminal and endometrial levels of
      various cytokines and growth factors will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trouble with recruting
  </why_stopped>
  <start_date type="Actual">January 21, 2014</start_date>
  <completion_date type="Actual">November 28, 2014</completion_date>
  <primary_completion_date type="Actual">November 28, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of uNK/CD56 cells per field</measure>
    <time_frame>baseline (Day 0) - 3 months</time_frame>
    <description>Number of cells per field from endometrial biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change in IL-1 beta titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in IL-12 titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in IL-15 titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in IL-18 titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in TWEAK titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in TNF-alpha titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in G-CSF titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in G-CSF receptor titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in VEGF titration in uterine flushing sample</measure>
    <time_frame>baseline (day 0) - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of macrophage cells per field on endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of T cells per field on endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of IL-1 beta in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of IL-12 in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of IL-15 in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of IL-18 in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of TWEAK in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of TNF-alpha in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of G-CSF in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of G-CSF receptor in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of VEGF in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of beta-2 microglobulin in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of RPL13A (reference gene) in endometrial biopsy</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endometrial volume (cm^3)</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subendometrial vascular flow index</measure>
    <time_frame>baseline (day 0) to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time needed for Essure deployment (minutes)</measure>
    <time_frame>baseline (day 0), immediatly after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of anesthesia used for Essure deployment</measure>
    <time_frame>baseline (day 0), immediatly after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spirals visible in the left uterine cavity after Essure deployment</measure>
    <time_frame>baseline (day 0), immediatly after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spirals visible in the right uterine cavity after Essure deployment</measure>
    <time_frame>baseline (day 0), immediatly after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of bilateral tube obstruction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of uNK/CD56 cells per field</measure>
    <time_frame>2 months before intervention - Day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2</enrollment>
  <condition>Sterilization, Tubal</condition>
  <arm_group>
    <arm_group_label>10 patients</arm_group_label>
    <description>The patients included desire tubal sterilization via the ESSURE technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Essure</intervention_name>
    <description>Essure devices are deployed according to manufacturer's instructions for tubal sterilization.</description>
    <arm_group_label>10 patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All left over samples will be included in the hematology biological collection at the Nîmes
      University Hospital.

      Endometrial flushing samples will also be included in the Nîmes University Hospital biobank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ten women desiring tubal sterilization via the ESSURE method.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given his/her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is available for 3 months of follow up

          -  The patient has had at least one child

          -  The patient desires definitive tubal sterilization via the ESSURE technique

          -  The legal delay of 4 months between request for sterilization and surgery has been
             respected

          -  Local contraception (condom or spermicide) must be used for three months before and
             after tubal sterilization

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  The patient is pregnant, parturient, or breastfeeding

          -  The patient had a diagnosed pregnancy (this includes pregnancies lost or interruptions
             in the 2nd or 3rd trimester) within the 4 months before ESSURE implants

          -  The patient has a contraindication for a treatment used in this study

          -  The patient uses one of the following types of contraception: intrauterine device;
             oestroprogestatif (pill).

          -  Endometriosis

          -  Gynecological infection

          -  adenomyosis

          -  uterine polyp

          -  uterine surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Letouzey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHP - Hôpital Antoine Beclere</name>
      <address>
        <city>Clamart Cedex</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essure</keyword>
  <keyword>Change in uterine cytokines</keyword>
  <keyword>Change in uterine natural killer cells</keyword>
  <keyword>cytokine</keyword>
  <keyword>natural killer cell</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

